Cancer Vaccines 2.0
This article was originally published in Start Up
Executive Summary
A trio of well-funded and star-studded new private biotechs have emerged in recent months to develop personalized cancer vaccines against tumor-specific neoantigens. After years of failure in the space, will Neon Therapeutics, Gritstone Oncology, Caperna and the rest of the field catch the wave of immuno-oncology science and sentiment?
You may also be interested in...
Can Drugs Targeting Tumor Microenvironment Unleash Cancer Vaccine Potential?
Cancer vaccines in the past have failed clinically but may have succeeded biologically, according to Roche R&D exec Hy Levitsky. The immunosuppressive tumor microenvironment must be circumvented if the vaccine response is to be effective – and Roche thinks its immuno-oncology pipeline could do the trick.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
CNS IPOs Follow Broad Industry Trends
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.